Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including Biogen (BIIB)/Eisai’s Leqembi and Lilly’s Kisunla on an Analyst/Industry conference call to be held on November 13 at 11 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Questions or Comments about the article? Write to editor@tipranks.com